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cytes, or natural killer cells (Roark
et al., 2008).
Taken together, our results indicate
that Th17 and IL-17 pathway are active
in BD patients, and has an important
role particularly in acute attacks of the
disease. Neutrophil activity is increased
in BD, and the affected organs show a
significant neutrophile infiltration.
Our data suggest that this result might
be caused by increased IL-17A res-
ponse in patients with BD. Treatment
modalities attempting to evaluate novel
approaches to eliminate the overactiv-
ity of IL-17A and/or IL-23–Th17 path-
way may clarify the biological
importance of IL-17A and Th17 cells
in patients with BD.
Our study, however, had also some
limitations. It is wise to keep in mind
that the increased IL-17A serum levels
is not clinical sign-specific and even
not disease-specific; it indicates inflam-
mation during the acute phases of
the disease with involvement of neu-
trophils. It might have been of more
scientific value to investigate longitudi-
nal evaluation of IL-17A and other
cytokine (IL-6, IL-8, tumor necrosis
factor-a, and so on) serum levels in a
group of patients with active and
inactive periods of the disease.
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TO THE EDITOR
I read with interest the study by Harder
et al. (2010), as they confirmed the
previous finding that the human b
defensin-2 (hBD-2) level in atopic
dermatitis (AD) lesions is lower than
that in psoriatic lesions, but higher than
healthy skin (Ong et al., 2002).
Based on the observation that psor-
iasis patients rarely suffer from skin
infections (Henseler and Christophers,
1995), Harder et al. (1997) made their
seminal discovery of hBD-2 in psoriatic
lesions. This antimicrobial peptide
(AMP) has since been proven to be the
strongest and most psoriasis-specific
protein (de Jongh et al., 2005; Gam-
bichler et al., 2008). In addition, it has
been shown to have immunomodula-
tory effects on innate and adaptive
immunity (Yang et al., 1999). Although
hBD-2 has weak direct antimicrobial
activity against Staphylococcus aureus
(Harder et al., 1997), the amount of
hBD-2 present in psoriatic lesions sig-
nificantly exceeds the amount required
for both antimicrobial effects (2.5–25mM)
and immunomodulation (2.5–250nM)
(Jansen et al., 2009). On the other hand,
the amount of hBD-2 present in AD
lesions, although higher than that in
healthy skin, has not been proven to
exceed these ranges. Furthermore, corre-
lation between hBD-2 level and clinical
infection in AD has not been studied.
However, the findings of Harder et al.
Abbreviations: AD, atopic dermatitis; AMP, antimicrobial peptide; CCR6, chemokine receptor; hBD-2,
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(2010) do raise the interesting question as
to how the presence of other AMPs,
which apparently have good direct anti-
S. aureus activity, is incapable of con-
trolling skin infections in AD.
Although recent studies have focused
on the regulation of AMPs by adaptive
immunity, it is not clear how the
relatively high expression of IL-22, a
key cytokine of adaptive immunity that
regulates AMPs, does not appear to
upregulate hBD-2 level in AD (Wolk
et al., 2004). hBD-2 has led the way in
studies of AMPs’ effects on adaptive
immunity (Yang et al., 1999). It binds
and attracts cells expressing the chemo-
kine receptor, CCR6 (Ro¨hrl et al., 2010).
A significant proportion of CCR6-expres-
sing T helper cells also produce IFN-g, IL-
17, and/or IL-22 (Ong and Leung, 2002;
Duhen et al., 2009). The increased and
decreased expression of IFN-g/IL-17 in
psoriatic and AD lesions, respectively
(Lowes et al., 2008) (Guttman-Yassky
et al., 2008), are not inconsistent with
the ability of hBD-2 to drive adaptive
immunity against skin infections. How-
ever, this hypothesis needs to be verified
further. As a proportion of AD patients are
not affected by skin infections (David and
Cambridge, 1986), it may be of interest to
evaluate whether there is any correlation
between hBD-2 level and clinical infec-
tion in AD. Further studies on the exact
role of hBD-2 in adaptive immunity are
needed before it is dismissed in relation
to the skin infections in AD.
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TO THE EDITOR
Bogh et al. (2010) recently found that
the increase in 25-(OH)-hydroxychole-
calciferol (25-(OH)-D) after UV-B ex-
posure in 28 non-sun-worshippers was
positively correlated with baseline total
cholesterol levels. In their discussion of
this interesting observation, the authors
cite from a biochemistry textbook:
The synthesis of vitamin D starts in
the bowel epithelial with the oxida-
tion of cholesterol from food or bile to
pro-vitamin D3 (7-dehydrocholester-
ol), which is then transported to the
skin, mainly the epidermis, wherein it
is isomerized to pre-vitamin D3
(cholecalciferol) by UVB radiation
(Champe et al., 2005).
A similar statement (regarding the
formation of 7-dehydrocholesterol in
the intestine and its transport to the
skin) is on page 732 in the most recent
(10th) edition of a German Pharmacol-
ogy textbook (Flockerzi, 2009).
Although we have no access to the
cited textbook of Champe et al. (2005),
in the textbook by Rang et al. (1995),
one can find on page 449:
Cholecalciferol (D3) generated in the
skin from 7-dehydrocholesterol by
the action of ultraviolet radiation,
the 7-dehydrocholesterol having
been formed from cholesterol in the
wall of the intestine.
A biochemistry textbook (Campbell
and Farrell, 2009) shows in Figure 8.30
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